<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39384330</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2059-7908</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>BMJ global health</Title><ISOAbbreviation>BMJ Glob Health</ISOAbbreviation></Journal><ArticleTitle>Malaria vaccine rollout begins in Africa: the need to strengthen regulatory and safety surveillance systems in Africa.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e015445</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjgh-2024-015445</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duga</LastName><ForeName>Alemayehu Lelisa</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0003-3944-1025</Identifier><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia alemayehud@africacdc.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Doctoral School Societies Politics, Public Health, Pharmacoepidemiology and Pharmacovigilance, University of Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngongo</LastName><ForeName>Ngashi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fallah</LastName><ForeName>Mosoka Papa</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueras</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Doctoral School Societies Politics, Public Health, Pharmacoepidemiology and Pharmacovigilance, University of Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilowe</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murtala</LastName><ForeName>Jibril</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayumba</LastName><ForeName>Kizito</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angasa</LastName><ForeName>Tedi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuba</LastName><ForeName>Aminu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabwe</LastName><ForeName>Patrick Chanda</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dereje</LastName><ForeName>Nebiyu</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5406-4171</Identifier><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raji</LastName><ForeName>Tajudeen</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ndembi</LastName><ForeName>Nicaise</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaseya</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Glob Health</MedlineTA><NlmUniqueID>101685275</NlmUniqueID><ISSNLinking>2059-7908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017780">Malaria Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000349" MajorTopicYN="N" Type="Geographic">Africa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017780" MajorTopicYN="Y">Malaria Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008288" MajorTopicYN="Y">Malaria</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Global Health</Keyword><Keyword MajorTopicYN="N">Immunisation</Keyword><Keyword MajorTopicYN="N">Malaria</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>21</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39384330</ArticleId><ArticleId IdType="pmc">PMC11474706</ArticleId><ArticleId IdType="doi">10.1136/bmjgh-2024-015445</ArticleId><ArticleId IdType="pii">bmjgh-2024-015445</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  Malaria. 2023. https://www.who.int/news-room/fact-sheets/detail/malaria Available.</Citation></Reference><Reference><Citation>Hamilton A, Haghpanah F, Hasso-Agopsowicz M, et al.  Modeling of malaria vaccine effectiveness on disease burden and drug resistance in 42 african countries. 2023. https://www.nature.com/articles/s43856-023-00373-y Available.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10576074</ArticleId><ArticleId IdType="pubmed">37833540</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . WHO; 2023. WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization.https://www.who.int/news/item/02-10-2023-who-recommends-r21-matrix-m-vaccine-for-malaria-prevention-in-updated-advice-on-immunization Available.</Citation></Reference><Reference><Citation>WHO; 2023. 18 million doses of first-ever malaria vaccine allocated to 12 african countries for 2023–2025: GAVI, WHO and UNICEF.https://www.who.int/news/item/05-07-2023-18-million-doses-of-first-ever-malaria-vaccine-allocated-to-12-african-countries-for-2023-2025--gavi--who-and-unicef Available.</Citation></Reference><Reference><Citation>Ndagije HB, Walusimbi D, Atuhaire J, et al. Drug safety in Africa: a review of systems and resources for pharmacovigilance. Expert Opin Drug Saf. 2023;22:891–5. doi: 10.1080/14740338.2023.2251375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2023.2251375</ArticleId><ArticleId IdType="pubmed">37676033</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayrit MM, Mendoza RU, Valenzuela SA. The importance of effective risk communication and transparency: lessons from the dengue vaccine controversy in the Philippines. J Public Health Policy . 2020;41:252–67. doi: 10.1057/s41271-020-00232-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1057/s41271-020-00232-3</ArticleId><ArticleId IdType="pubmed">32518285</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackah BBB, Woo M, Stallwood L, et al. COVID-19 vaccine hesitancy in Africa: a scoping review. Glob Health Res Policy. 2022;7:21. doi: 10.1186/s41256-022-00255-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41256-022-00255-1</ArticleId><ArticleId IdType="pmc">PMC9294808</ArticleId><ArticleId IdType="pubmed">35850783</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)  List of national regulatory authorities (NRAs) operating at maturity level 3 (ML3) 1 and maturity level 4 (ML4) 2 (as benchmarked against who global benchmarking tool (GBT) 2023. https://www.who.int/publications/m/item/list-of-nras-operating-at-ml3-and-ml4 Available.</Citation></Reference><Reference><Citation>Yue QY. The International Society of Pharmacovigilance (ISoP) Pharmacogenomic Special Interest Group: Pharmacogenomics in Pharmacovigilance. Drug Saf. 2021;44:615–7. doi: 10.1007/s40264-021-01068-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-021-01068-w</ArticleId><ArticleId IdType="pmc">PMC8184708</ArticleId><ArticleId IdType="pubmed">33964001</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . COVID-19 Vaccines: Safety Surveillance Manual. 2nd. 2021. edn.</Citation></Reference><Reference><Citation>European medicines agency  . EMA website; 2021. COVID-19 vaccines: development, evaluation, approval and monitoring | European medicines agency.https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-public-health-emergency-international-concern-2020-23/covid-19-vaccines-development-evaluation-approval-and-monitoring Available.</Citation></Reference><Reference><Citation>Africa CDC  Africa CDC renews its commitment to reduce vaccine-preventable diseases and outbreaks in Africa – Africa CDC. 2024. https://africacdc.org/news-item/africa-cdc-renews-its-commitment-to-reduce-vaccine-preventable-diseases-and-outbreaks-in-africa/ Available.</Citation></Reference><Reference><Citation>Time  Cameroon starts world-first malaria vaccine program for kids. 2024. https://time.com/6565005/cameroon-malaria-vaccines/ Available.</Citation></Reference><Reference><Citation>Ndomondo-Sigonda M, Miot J, Naidoo S, et al. Harmonization of medical products regulation: a key factor for improving regulatory capacity in the East African Community. BMC Public Health. 2021;21:187. doi: 10.1186/s12889-021-10169-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-10169-1</ArticleId><ArticleId IdType="pmc">PMC7818747</ArticleId><ArticleId IdType="pubmed">33478421</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Mesquida MÀ, Oms-Arias M, Diogène-Fadini E, et al. Safer prescription of drugs: impact of the PREFASEG system to aid clinical decision-making in primary care in Catalonia. BMC Med Inform Decis Mak. 2021;21:349. doi: 10.1186/s12911-021-01710-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-021-01710-8</ArticleId><ArticleId IdType="pmc">PMC8675496</ArticleId><ArticleId IdType="pubmed">34911534</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieu TA, Kulldorff M, Davis RL, et al. Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events. Med Care. 2007;45:S89–95. doi: 10.1097/MLR.0b013e3180616c0a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e3180616c0a</ArticleId><ArticleId IdType="pubmed">17909389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low‐ and middle‐income countries: A review with particular focus on Africa. Brit J Clin Pharma. 2023;89:491–509. doi: 10.1111/bcp.15193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15193</ArticleId><ArticleId IdType="pubmed">34937122</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>